Alexion Pharmaceuticals Inc.

ALXN

$182.50

0.0% (1 year change)

Market Cap

$0

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

52 Week Range

$0.00 - $0.00

The lowest and highst price in the last 52 weeks.

Price-Earnings Ratio

0.0x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

Dividends per Share

$0.00 (0.0%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Revenue & Earnings

Balance Sheet

Share Statistics

Market Cap $0
Enterprise Value -$937 Million
Dividend Yield $0.00 (0.0%)
1 Year Return 0.0%
52-Week High $0.00
52-Week Low $0.00
Beta 0.0
Outstanding Shares 221 Million
Avg 30 Day Volume 0

Valuation

P/E Ratio 0.0
PEG 0.0
Earnings per Share $3.07
Price to Sales Ratio 6.52
Price to Book Ratio 3.26
Revenue to Enterprise Value -0.15
EBIT to Enterprise Value -0.32
Total Debt to Enterprise Value -2.7
Debt to Equity 0.2

Profitability

Revenue $6.26 Billion
Gross Profit $5.69 Billion
EBIT $2.95 Billion
Net Income $682 Million
Profit Margin 10.89%
Quarterly Earnings Growth (YoY) +14.1%
Return on Equity 5.49%
Return on Assets 3.66%
Return on Invested Capital 17.11%

Insider trades

No purchases

No sells

No purchases

No sells

No purchases

No sells

No purchases

No sells

Q1 2021 Q2 2021 Q3 2021 Q4 2021

About Alexion Pharmaceuticals Inc.

CEO: Leonard Bell

Industry: Pharmaceutical Preparation Manufacturing

Similar stocks

Gilead Sciences, Inc.
Regeneron Pharmaceuticals, Inc.
Vertex Pharmaceuticals, Inc.
Biogen Inc
Qiagen NV
Agios Pharmaceuticals Inc
Ultragenyx Pharmaceutical Inc.
Sarepta Therapeutics Inc
Bio-Rad Laboratories Inc. - Class B
Johnson & Johnson

News

ICER finds Alexion''s Soliris lacks cost-effectiveness for myasthenia gravis

ICER finds Alexion''s Soliris lacks cost-effectiveness for myasthenia gravis

No summary available.

Seeking Alpha Seeking Alpha, 3 months ago
Acquisition of Alexion completed

Acquisition of Alexion completed

21 July 2021 13:45 BST NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN View post on CompanyNewsHQ : Acquisition of Alexion completed

CompanyNewsHQ CompanyNewsHQ, 3 months ago
Alexion Pharmaceuticals Stock Appears To Be Modestly Overvalued

Alexion Pharmaceuticals Stock Appears To Be Modestly Overvalued

Related Stocks: ALXN ,

GuruFocus GuruFocus, 3 months ago